Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2013 / Cilt: 47 - Sayı: 4

Three-year observation of the patients with bullous pemphigoid: 29 cases

Büllöz pemfigoidli hastalarda 3 yıllık gözlem: 29 olgu

Pages
205–208
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nevertheless, prospective, long-term and large population-based multicentestudies are needed. (Turkderm 2013; 47: 205-8)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal blistering skin disease.
📊
Key Findings & Data:Materials and Methods: We retrospectively evaluated medical records of patients with BP diagnosed by clinical and histopathologicaexaminations in our clinic from January 2009 to January 2013.
💡
Conclusion & Impact:Nevertheless, prospective, long-term and large population-based multicentestudies are needed. (Turkderm 2013; 47: 205-8)
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Background and Design: Bullous pemphigoid (BP) is a chronic, autoimmune, subepidermal blistering skin disease. The aim of this study was to determine the clinico-epidemiological characteristics of patients diagnosed with BP in our clinic and to compare the results with those in othestudies in our country and in the world. Materials and Methods: We retrospectively evaluated medical records of patients with BP diagnosed by clinical and histopathologicaexaminations in our clinic from January 2009 to January 2013. We evaluated data on demographic characteristics, age, sex, existence of oramucosal lesions, association of pruritus, duration of the disease, presence of triggering factors, features of the skin lesions, results of direcimmunofluorescence (DIF) investigations, drug intake, recurrence and mortality rates and causes of de-tected mortality in all patients. Results: Of the 29 patients included in the study, %48.3 were female, %51.7 were male. The average age was 70.17 years and the mean duration of the disease was 15.41 months. We detected oral mucosal involvement in five cases, and pruritus in 24 patients. Drugs use in three cases and malinity in one patient were considered be be an trigger factor. The results of DIF investigation revealed linear IgG and C3 deposition at the dermoepidermal junction in 12 cases and C3 deposition in 10 cases. The initial treatment was topical corticosteroid in 11tetracycline and nicotinamide combination in six and systemic corticosteroid in 10 individuals. After initial therapy, recurrence appeared in 7 patients within one year. Mortality during hospitalization was observed in 2 cases. Conclusion: We presented the clinical and epidemiological features of patients diagnosed with BP in our clinics in the past three yearsConsidering the presence of different ethnic groups and population heterogenity in our city, we believe that our investigation will contributto our understanding of the epidemiology of BP in our country. Nevertheless, prospective, long-term and large population-based multicentestudies are needed. (Turkderm 2013; 47: 205-8)

Özet

Amaç: Büllöz pemfigoid (BP) kronik, otoimmun subepidemal büllöz bir hastalıktır. Çalışmamızdaki amaç, son 3 yılda kliniğimizde BP tanısı konulan olguların klinik ve epidemiyolojik özelliklerini belirlemek ve sonuçlarımızı ülkemizdeki ve dünyanın diğer yerlerindeki sonuçlarla karşılaştırmaktır. Gereç ve Yöntem: Ocak 2009 ve Ocak 2013 tarihleri arasında Dermatoloji polikliniğimize başvuran, klinik ve histopatolojik olarak BP tanısı alan hastaların dosyaları retrospektif olarak değerlendirildi. Hastaların yaş, cinsiyet, oral mukoza tutulumu, kaşıntının varlığı, hastalık süresi, tetikleyici faktör bulunup bulunmaması, deri lezyonlarının özellikleri, biyopsi örneklerinin direk immünofloresan (DIF) inceleme sonuçları, tedavide kullanılan ilaçlar, nüks ve eksitus oranları ve saptanabilen ölüm nedenleri gibi klinik ve demografik verileri kaydedildi. Bulgular: Çalışmaya alınan 29 hastanın %48,3'ü kadın, %51,7'i erkekti. Yaş ortalamaları 70,17 yıl iken, ortalama hastalık suresi 15,41 aydı. Oral mukoza tutulumu beş, kaşıntı 24 olguda saptandı. Tetikleyici faktör olarak üç olguda ilaç, bir olguda da malinite belirlendi. DIF inceleme sonuçlarında dermoepidermal bileşkede lineer IgG ve C3 depolanması 12 olguda, C3 depolanması 10 olguda mevcuttu. Hastalara başlangıç tedavisi olarak 11 hastaya topikal kortikosteroid, altı hastaya tetrasiklin and nikotinamid kom-binasyonu, 10 hastaya sistemik kortikosteroid tedavisi verildi. Yedi hastada verilen ilk tedaviden sonra bir yıl içinde nüks meydana geldi. Hastane içi mortalite iki hastada görüldü. Sonuç: Çalışmamızda son 3 yılda kliniğimizde BP tanısı konulan hastalarının klinik ve epidemiyolojik verileri sunulmuştur. İlimiz farklı etnik gruplardan oluşan heterojen bir popülasyon olduğu için, çalışmamızın ülkemizdeki BP ile ilgili epidemiyolojik verilerin oluşturulmasında katkıda bulunacağına inanıyoruz. Ancak bu konuda yapılmış prospektif, daha uzun süreli ve çok merkezli çalışmalara ihtiyaç duyulmaktadır. (Türk­derm 2013; 47: 205-8)

🔖

Cite This Article

EKİZ, Ö., RİFAİOĞLU, E. N., ŞEN, T., ÇİĞDEM, A. D., BÜLBÜL, B. Ş. (2022). Three-year observation of the patients with bullous pemphigoid: 29 cases. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 47 - Sayı: 4, 205–208. https://ajindex.com/articles/622296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Wojnarowska F, Venning VA, Burge SM: Immunobullous diseases. Rook’s Textbook of Dermatology. Ed. Burns T, Breathnach S, Cox N, Griffiths C. 7'nci baskı. Oxford, Blackwell Science 2004;41:1-41.
  2. Jung M, Kipper W, Messer G, et al: Increased risk of bullous pemphigoid in male and very old patients: a population based populationbased study on incidence. J Am Acad Dermatol 1999;41:266-8.
  3. Kirtschig G, Wojnarowska F: Autoimmune blistering diseases: an up-date of diagnostic methods and investigations. Clin Exp Dermatol 1994;19:97-112. Adam BA: Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol 1992;31:42-5.
  4. Triki Ben Ammar S, Mokhtar I, Fazaa B, Kharfi M, Kamoun MR: Profile of bullous pemphigoid. A report of 47 cases. Tunis Med 2000;78:584-8.
  5. Wong SN, Chua SH: Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol 2002;147:476-80.
  6. Chang YT, Liu HN, Wong CK: Bullous pemphigoid a report of 86 cases from Taiwan. Clin Exp Dermatol 1996;21:20-2.
  7. Zillikens D, Wever S, Hashimoto T, Brocker EB: Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 1995;131:957–8. Bernard P, Vaillant L, Labeille B, et al: Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Arch Derma-tol 1995;131:48-52.
  8. Cozzani E, Parodi A, Reboria A et al: Bullous pemphigoid in Liguria: a 2-year survey. J Eur Acad Dermatol Venereol 2001;15:317-19.
  9. Marazza G, Pham HC, Scharer L, et al: Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009;161:861-8.
  10. Bertram F, Brocker EB, Zillikens D, Schmidt E: Prospective analysis of the in- cidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 2009;7:434-40.
  11. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA: Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol 2004;43:876-81.
  12. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al: Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics. J Am Acad Dermatol 2008;58:41-8.
  13. Uzun S, Durdu M, Akman A, et al: Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. Int J Dermatol 2006;45:523-8.
  14. Akay B.N, Bodamyalı P, Şanlı H, Akyol A: Bülloz Pemfigoidli Hastalarda 10 Yıllık Gözlem. Türkderm-Deri Hastalıkları ve Frengi Arşivi Dergisi 2010;44:61- 4. Lebe B, Niflioğlu GG, Seyrek S, Ellidokuz H: Otoimmün V